Literature DB >> 22329295

[Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation].

Natasa Beader1, Smilja Kalenić, Boris Labar.   

Abstract

In spite of improvements in diagnostics and prevention of CMV disease in recent decades, CMV infection still remains major concern in terms of diagnosis and therapy in recipients of allogeneic stem cells. Besides considerable morbidity with direct effects of CMV infection (hepatitis, gastrointestinal disease, pneumonia, retinitis), there are also indirect effects such as increased susceptibility to opportunistic infections and an increased risk of graft rejection and transplant-related mortality. Also, myelosuppression, nephrotoxicity and emergence of drug-resistant CMV strains may limit the use of antiviral agents for the control of CMV infection. The aim of this paper is to show the problems associated with CMV infection in recipients of allogeneic stem cells with special emphasis on diagnostic procedures and treatment or prophylaxis of CMV disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22329295

Source DB:  PubMed          Journal:  Lijec Vjesn        ISSN: 0024-3477


  3 in total

1.  Infection status of human parvovirus B19, cytomegalovirus and herpes simplex Virus-1/2 in women with first-trimester spontaneous abortions in Chongqing, China.

Authors:  Ya-Ling Gao; Zhan Gao; Miao He; Pu Liao
Journal:  Virol J       Date:  2018-04-23       Impact factor: 4.099

2.  Seroepidemiology of cytomegalovirus infections in Croatia.

Authors:  Tatjana Vilibic-Cavlek; Branko Kolaric; Natasa Beader; Izabela Vrtar; Irena Tabain; Gordana Mlinaric-Galinovic
Journal:  Wien Klin Wochenschr       Date:  2016-09-06       Impact factor: 1.704

Review 3.  Fulminant gastrointestinal graft-versus-host disease concomitant with cytomegalovirus infection: case report and literature review.

Authors:  Hidetaka Okubo; Naoyoshi Nagata; Naomi Uemura
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.